Disclosures MCG reports grants and personal fees from Eli Lilly, Otsuka Pharma, Astra Zeneca, Novartis, BMS, Roche, Pfizer, Celgene, Incyte, Bayer, MSD, GlaxoSmithKline S.p.A., Sanofi-Aventis, Spectrum Pharmaceuticals, and Blueprint Medicine; personal fees from Boehringer Ingelheim, Inivata, Takeda, Seattle Genetics, Daiichi Sankyo, Janssen, and Mirati Therapeutics, Regeneron Pharmaceuticals; grants from Tiziana Sciences, Clovis, Merck Serono, United Therapeutics Corporation, Merck KGaA, Turning Point, Ipsen, MedImmune, Exelixis, Pfizer, and BMS & Celgene; nonfinancial support from MSD and Eli-Lilly. MV reports being an employee of the European Society for Medical Oncology. EdV reports institutional financial support for her advisory/consultancy role from Daiichi Sankyo, NSABP, and Crescendo Biologics, and institutional financial support for clinical trials or contracted research from Amgen, Bayer, CytomX Therapeutics, G1 Therapeutics, Genentech, Regeneron, Roche, Servier, and Synthon, all outside the submitted work. RK reports advisory board/speaker/received honoraria from J&J, Astellas, MSD, BMS, Amgen, Pfizer, Ipsen, AstraZeneca, and Eisai. RG reports being a core member of the European Medicines Agency Scientific Advisory Group-Oncology, an expert evaluator for the EU Commission on the topic ‘Global Alliance for Chronic Diseases (GACD) 2 – Prevention and/or early diagnosis of cancer’; provides consultation/lectures (no remuneration) for Novartis, Mylan, Roche, Lilly, and Apogen; and institutional financial support (clinical trials, Italy) from MSD and Novartis. SP reports education grants, provided consultation, attended advisory boards, and/or provided lectures for the following organisations, from which she has received honoraria: AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Incyte, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Phosphoplatin Therapeutics, Pfizer, Regeneron, Sanofi, Seattle Genetics, and Takeda (Consultation/advisory role); AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Illumina, Medscape, Merck Sharp and Dohme, Novartis, Pfizer, Prime, Sanofi, and Takeda (Talk in a company's organised public event); receipt of grants/research supports/(sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, F. Hoffmann-La Roche, GSK, Illumina, Lilly, Merck Sharp and Dohme, Merck Serono, Mirati, Novartis, Pfizer, and Phoshoplatin Therapeutics.